Free Trial
NASDAQ:IRD

Opus Genetics 8/13/2025 Earnings Report

Opus Genetics logo
$1.14 -0.02 (-1.72%)
As of 03:08 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Opus Genetics EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Opus Genetics Revenue Results

Actual Revenue
$2.88 million
Expected Revenue
$4.27 million
Beat/Miss
Missed by -$1.39 million
YoY Revenue Growth
N/A

Opus Genetics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Opus Genetics Earnings Headlines

GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.tc pixel
See More Opus Genetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email.

About Opus Genetics

Opus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

View Opus Genetics Profile

More Earnings Resources from MarketBeat